This is the fourth year TISSIUM has been included in the program for late-stage startups
Paris, France, February 20th, 2023 — TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, confirms its selection for the fourth year in a row in the French Tech 120 Program by joining the class of 2023, the most selective class since the creation of the program.
Launched in 2019 by the Mission French Tech, the French Tech 120 is a program from the Government to support the most promising French start-ups, who have the potential to become world-class technology leaders.
TISSIUM will benefit from daily, personalized support throughout 2023. The aim of the program is to provide individual and collective support on strategic issues such as international development, financing, recruitment, industrial implantation, intellectual property, and regulatory issues. Start-ups will thus be able to rely on a dedicated start-up manager within the Mission French Tech, enhanced visibility, specific support on regulatory issues, and collective support in the form of experience-sharing events and expertise contributions.
2023 will be an important year for TISSIUM with important milestones to be reached in all verticals; especially when it comes to the final steps towards the commercialization of its first products in 2024.
“We are delighted to be part, once again, of the French Tech 120 program, especially considering a 2023 year that will mark the achievement of important milestones regarding our strategic plan and further expansion of our growing business in light of the upcoming commercialization of our first products in 2024. For the fourth year in a row, our participation in the French Tech 120 continues to be a staple of recognition in our ongoing efforts of transforming tissue repair” said Christophe Bancel, CEO of TISSIUM.
